# Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD

> **NCT06192004** · — · TERMINATED · sponsor: **AstraZeneca** · enrollment: 83 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **OTHER:** None (Observational Study)

## Key facts

- **NCT ID:** NCT06192004
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2024-01-05
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 83 (ACTUAL)
- **Why stopped:** Observed event rate was below the rate required to meet study objectives.
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06192004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06192004, "Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06192004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*